<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061147</url>
  </required_header>
  <id_info>
    <org_study_id>MAX-40279-004</org_study_id>
    <nct_id>NCT05061147</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</brief_title>
  <official_title>A Single-arm, Multi-Center, Phase Ib/Ⅱ Clinical Trial of Max-40279-01 in Combination With Azacitidine (AZA) in Adult Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maxinovel Pty., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maxinovel Pty., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase Ib/II study of Max-40279-01 in combination with Azacitidine (AZA) in&#xD;
      patients with Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia&#xD;
      (R/R AML). This study include Phase Ib and Phase II study. The phase Ib study is designed to&#xD;
      evaluate the safety and tolerability of MAX-40279-01 in combination with Azacitidine (AZA) in&#xD;
      patients with Relapsed or Refractory AML. The phase II study is designed to preliminarily&#xD;
      assess the efficacy and safety of Max-40279-01 in combination with Azacitidine (AZA) in&#xD;
      patients with Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia&#xD;
      (R/R AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part study comprised of a dose escalation part and a dose expansion part.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Through study Part 1 completion, an average of 6 months</time_frame>
    <description>To explore the maximum tolerable dose (MTD) of Max-40279-01 in combination with Azacitidine (AZA) for patients with r/r AML or MDS, the recommended phase II dose (RP2D).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II dose (RP2D)</measure>
    <time_frame>Through study Part 1 completion, an average of 6 months</time_frame>
    <description>Recommended phase II dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of complete remission (CRc)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>including Complete Remission with incomplete Platelet recovery (CRp) and Complete Remission with incomplete hematologic recovery (CRi)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Maximum plasma drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Area under the time-concentration curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Observed terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 months (anticipated)</time_frame>
    <description>The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on IRWG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by incidence and severity of adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>All grade ≥ 3 toxicities according to CTCAE (Common Terminology Criteria for Adverse Events) version 5 will be tabulated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Relapsed/Refractory Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Max-40279-01 in combination with Azacitidine (AZA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open-label Phase Ib/II clinical study. The study will be conducted in two parts:&#xD;
Part I: Phase Ib dose escalation. Participants receive Max-40279-01 in combination with azacytidine (AZA), with different dose schedules.&#xD;
Part II: Phase II dose expansion. Participants divide into positive group and negative group according to whether FLT3 gene mutation occurs, approximately 40 people per group.&#xD;
All participants receive the recommended dose for Part 2 of Max-40279-01 with azacytidine (AZA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAX-40279-01</intervention_name>
    <description>Drug: AZA AZA will be administered at 75 mg/m^2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.&#xD;
Other Name: Azacitidine&#xD;
Drug: Max-40279-01 Max-40279-01 will be administered as a combination of multiple oral capsules containing 5 and 25 mg. An alternate combination of 35 mg, 50 mg and 60 mg Max-40279-01 twice a day may be utilized.&#xD;
Other Name: NA</description>
    <arm_group_label>Max-40279-01 in combination with Azacitidine (AZA)</arm_group_label>
    <other_name>Azacitidine (AZA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and/or females over age 18&#xD;
&#xD;
          2. A diagnosis of AML according to the World Health Organization (WHO) 2016 criteria with&#xD;
             relapsed or refractory disease and have exhausted, or are ineligible for therapeutic&#xD;
             options, or int-risk or high-risk or very high-risk MDS according to revised&#xD;
             International Prognostic Scoring System (IPSS-R);&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.&#xD;
&#xD;
          4. Expected survival &gt;3 months.&#xD;
&#xD;
          5. No radiotherapy, surgery or hormonal therapy for any kind of within 2 weeks prior to&#xD;
             participating in this study. Patients must have fully recovered from the acute&#xD;
             toxicities of any prior treatment with any anti-cancer drugs (including&#xD;
             hypomethylating agents in MDS patients), radiotherapy or other anti-cancer modalities&#xD;
             (i.e., returned to baseline status as noted before most recent treatment) for any&#xD;
             tumors. Patients with persisting, stable chronic toxicities from such prior treatment&#xD;
             ≤Grade 1 are eligible, but must be documented as such.&#xD;
&#xD;
          6. Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute promyelocytic leukemia according to World Health Organization 2016 criteria&#xD;
&#xD;
          2. Known central nervous system involvement&#xD;
&#xD;
          3. Medical history of difficulty swallowing, malabsorption or other chronic&#xD;
             gastrointestinal disease, or conditions that may hamper compliance and/or absorption&#xD;
             of the tested product&#xD;
&#xD;
          4. Known allergies, hypersensitivity, or intolerance to Max-40279-01 or AZA or the&#xD;
             excipients of these treatments&#xD;
&#xD;
          5. Previously treated malignancies other than the current disease, except for adequately&#xD;
             treated non-melanoma skin cancer, in situ cancer, or other cancer from which the&#xD;
             subject has been disease-free for at least 5 years at the trial entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanying Bao, MD,Ph.D</last_name>
    <phone>+86-021-51370693</phone>
    <email>hybao@maxinovel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianxiang Wang</last_name>
      <phone>86-22-23909278</phone>
      <email>wangjx@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>September 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed/Refractory Acute Myeloid Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

